Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

MLA

Russell, Heidi V., et al. “Rising Drug Cost Impacts on Cost-Effectiveness of 2 Chemotherapy Regimens for Intermediate-Risk Rhabdomyosarcoma: A Report from the Children’s Oncology Group.” Cancer, vol. 128, no. 2, Jan. 2022, pp. 317–25. EBSCOhost, https://doi.org/10.1002/cncr.33917.

APA

Russell, H. V., Chi, Y.-Y., Okcu, M. F., Bernhardt, M. B., Rodriguez-Galindo, C., Gupta, A. A., & Hawkins, D. S. (2022). Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children’s Oncology Group. Cancer, 128(2), 317–325. https://doi.org/10.1002/cncr.33917

Chicago

Russell, Heidi V, Yueh-Yun Chi, M Fatih Okcu, M Brooke Bernhardt, Carlos Rodriguez-Galindo, Abha A Gupta, and Douglas S Hawkins. 2022. “Rising Drug Cost Impacts on Cost-Effectiveness of 2 Chemotherapy Regimens for Intermediate-Risk Rhabdomyosarcoma: A Report from the Children’s Oncology Group.” Cancer 128 (2): 317–25. doi:10.1002/cncr.33917.